VLP Therapeutics Awarded $3.9 million Grant by Global Health Innovative Technology Fund for Further Development of Dengue Vaccine
December 12, 2018 Gaithersburg, MD - The Global Health Innovative Technology (GHIT) Fund has awarded VLP Therapeutics a $3.9 million grant to further develop a novel tetravalent dengue virus-like particle vaccine. “The GHIT Fund’s commitment
November 29, 2018 Dr. Wataru Akahata, CEO and Founder of VLP Therapeutics was Selected by the Government of Japan as a 2018 Researcher of Significant Contribution to Science Japan’s National Institute of Science and Technology
October 18, 2018 Gaithersburg, MD -- VLP Therapeutics announced the issuance of US Patent 10,098,943 titled, “Flavivirus virus-like particle” on October 16, 2018. This patent supports VLP Therapeutics’ Native Virus Modification virus-like particle platform on
VLP Therapeutics is Recognized by the Government of Japan (Cabinet Office) “Comprehensive Strategy on Science, Technology and Innovation for 2017”
VLP Therapeutics was recently recognized as one of eleven companies that exemplify Japan’s commitment to Innovation as outlined in the 2017 Comprehensive Strategy on Science, Technology and Innovation. In 2017 the Cabinet Office of the
Vaccines are one of the most important inventions in the past centuries. The successful vaccines save millions of lives by eradicating the epidemic and pandemic diseases. I left the research field and formed VLP Therapeutics because I am committed to developing the next generation vaccine technology to treat the diseases that currently lack effective treatment. We believe that our i-αVLP vaccine technology has a potential to create a breakthrough treatments and make significant contributions to the improvement of global public health.